Ovarian cancer treatment: The end of empiricism?

Por Lheureux, Stephanie, Karakasis, Katherine, Kohn, Elise C., Oza, Amit M.
Publicado no Cancer (2015)

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention

Por Karakasis, Katherine, Burnier, Julia V., Bowering, Valerie, Oza, Amit M., Lheureux, Stephanie
Publicado no Front Oncol (2016)

Estimation of expectedness: Predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer

Por Castonguay, Vincent, Wilson, Michelle K., Diaz‐Padilla, Ivan, Wang, Lisa, Oza, Amit M.
Publicado no Cancer (2014)

Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital

Por Ho, Jeremy, Pond, Gregory R, Newman, Colin, Maclean, Martha, Chen, Eric X, Oza, Amit M, Siu, Lillian L
Publicado em 2006

Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?

Por Chau, Nicole G, Florescu, Ana, Chan, Kelvin K, Wang, Lisa, Chen, Eric X, Bedard, Philippe, Oza, Amit M, Siu, Lillian L
Publicado em 2011

A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

Por Goss, Glenwood D., Jonker, Derek J., Laurie, Scott A., Weberpals, Johanne I., Oza, Amit M., Spaans, Johanna N., la Porte, Charles, Dimitroulakos, Jim
Publicado no J Transl Med (2016)

Efficacy and Safety of Bevacizumab Plus Erlotinib for Patients with Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer: A Trial of the Chicago, PMH, and California Ph...

Por Nimeiri, Halla S., Oza, Amit M., Morgan, Robert J., Friberg, Gregory, Kasza, Kristen, Faoro, Leonardo, Salgia, Ravi, Stadler, Walter M., Vokes, Everett E., Fleming, Gini F.
Publicado em 2008

A Phase II Study of Sorafenib in Advanced Uterine Carcinoma / Carcinosarcoma: A Trial of the Chicago, PMH, and California Phase II Consortia

Por Nimeiri, Halla S., Oza, Amit M., Morgan, Robert J., Huo, Dezheng, Elit, Laurie, Knost, James A., Wade, James L., Agamah, Edem, Vokes, Everett E., Fleming, Gini F.
Publicado em 2010

A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium

Por Taylor, Sara K., Chia, Stephen, Dent, Susan, Clemons, Mark, Agulnik, Mark, Grenci, Pamela, Wang, Lisa, Oza, Amit M., Ivy, Percy, Pritchard, Kathleen I., Leighl, Natasha B.
Publicado em 2010

Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom...

Por Sjoquist, Katrin M., Friedlander, Michael L., O'Connell, Rachel L., Voysey, Merryn, King, Madeleine T., Stockler, Martin R., Oza, Amit M., Gillies, Kim, Martyn, Julie K., Butow, Phyllis N.
Publicado em 2013

Better Therapeutic Trials in Ovarian Cancer

Por Bookman, Michael A., Gilks, C. Blake, Kohn, Elise C., Kaplan, Karen O., Huntsman, David, Aghajanian, Carol, Birrer, Michael J., Ledermann, Jonathan A., Oza, Amit M., Swenerton, Kenneth D.
Publicado em 2014

Phase II trial of the histone deacetylase inhibitor Belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumors

Por Mackay, Helen J., Hirte, Hal, Colgan, Terrence, Covens, Al, MacAlpine, Katrina, Grenci, Pamela, Wang, Lisa, Mason, Jaqueline, Pham, Pnu-An, Tsao, Ming-S, Pan, James, Zwiebel, James, Oza, Amit M.
Publicado em 2010

Randomized Phase II trial of Cyclophosphamide and the Oral Poly (ADP-ribose) Polymerase Inhibitor Veliparib in Patients with Recurrent, Advanced Triple-Negative Breast Cancer

Por Kummar, Shivaani, Wade, James L., Oza, Amit M., Sullivan, Daniel, Chen, Alice P., Gandara, David R., Ji, Jiuping, Kinders, Robert J., Wang, Lihua, Allen, Deborah, Coyne, Geraldine O’Sullivan, Steinberg, Seth M., Doroshow, James H.
Publicado no Invest New Drugs (2016)

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study

Por Oza, Amit M., Selle, Frédéric, Davidenko, Irina, Korach, Jacob, Mendiola, Cesar, Pautier, Patricia, Chmielowska, Ewa, Bamias, Aristotelis, DeCensi, Andrea, Zvirbule, Zanete, González-Martín, Antonio, Hegg, Roberto, Joly, Florence, Zamagni, Claudio, Gadducci, Angiolo, Martin, Nicolas, Robb, Stephen, Colombo, Nicoletta
Publicado no Int J Gynecol Cancer (2017)

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Por Oza, Amit M., Elit, Laurie, Tsao, Ming-Sound, Kamel-Reid, Suzanne, Biagi, Jim, Provencher, Diane Michele, Gotlieb, Walter H., Hoskins, Paul J., Ghatage, Prafull, Tonkin, Katia S., Mackay, Helen J., Mazurka, John, Sederias, Joana, Ivy, Percy, Dancey, Janet E., Eisenhauer, Elizabeth A.
Publicado em 2011

Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas

Por Stathis, Anastasios, Hotte, Sebastien J., Chen, Eric X., Hirte, Holger W., Oza, Amit M., Moretto, Patricia, Webster, Sheila, Laughlin, Anne, Stayner, Lee-Anne, McGill, Shauna, Wang, Lisa, Zhang, Wen-jiang, Espinoza-Delgado, Igor, Holleran, Julianne L., Egorin, Merrill J., Siu, Lillian L.
Publicado em 2009

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors

Por Diaz-Padilla, Ivan, Hirte, Hal, Oza, Amit M., Clarke, Blaise A., Cohen, Brenda, Reedjik, Michael, Zhang, Tong, Kamel-Reid, Suzanne, Ivy, S. Percy, Hotte, Sebastien J., Razak, Albiruni A. R., Chen, Eric X., Brana, Irene, Wizemann, Monika, Wang, Lisa, Siu, Lillian L., Bedard, Philippe L.
Publicado em 2013

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)

Por Richter, Suzanne, Bedard, Philippe L., Chen, Eric Xueyu, Clarke, Blaise A., Tran, Ben, Hotte, Sebastien J., Stathis, Anastasios, Hirte, Hal W., Razak, Albiruni R. A., Reedijk, Michael, Chen, Zhuo, Cohen, Brenda, Zhang, Wen-Jiang, Wang, Lisa, Ivy, S. Percy, Moore, Malcolm J., Oza, Amit M., Siu, Lillian L., McWhirter, Elaine
Publicado em 2013

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

Por Berinstein, Neil L, Karkada, Mohan, Oza, Amit M, Odunsi, Kunle, Villella, Jeannine A, Nemunaitis, John J, Morse, Michael A, Pejovic, Tanja, Bentley, James, Buyse, Marc, Nigam, Rita, Weir, Genevieve M, MacDonald, Lisa D, Quinton, Tara, Rajagopalan, Rajkannan, Sharp, Kendall, Penwell, Andrea, Sammatur, Leeladhar, Burzykowski, Tomasz, Stanford, Marianne M, Mansour, Marc
Publicado no Oncoimmunology (2015)

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Por Oza, Amit M, Cook, Adrian D, Pfisterer, Jacobus, Embleton, Andrew, Ledermann, Jonathan A, Pujade-Lauraine, Eric, Kristensen, Gunnar, Carey, Mark S, Beale, Philip, Cervantes, Andrés, Park-Simon, Tjoung-Won, Rustin, Gordon, Joly, Florence, Mirza, Mansoor R, Plante, Marie, Quinn, Michael, Poveda, Andrés, Jayson, Gordon C, Stark, Dan, Swart, Ann Marie, Farrelly, Laura, Kaplan, Richard, Parmar, Mahesh K B, Perren, Timothy J
Publicado no Lancet Oncol (2015)